All patients (n = 20) | Stent diameter < 4 mma (n = 15) | |||||
---|---|---|---|---|---|---|
N (%) | N (%) | p | N (%) | N (%) | p | |
Cross-sectional analysis (number of struts) | Absorb (229) | Synergy (191) | Absorb (229) | Synergy (89) | ||
Lumen area (mm2) | 6.61 ± 2.12b | 9.48 ± 2.50 | < 0.001 | 6.61 ± 2.12 | 7.67 ± 1.67 | < 0.001 |
Adluminal stent/scaffold area (mm2) | 8.52 ± 2.15 | 11.23 ± 2.72 | < 0.001 | 8.52 ± 2.15 | 9.32 ± 1.74 | 0.002 |
Endoluminal stent/scaffold area (mm2) | 6.65 ± 2.01 | 9.72 ± 2.48 | < 0.001 | 6.65 ± 2.01 | 8.00 ± 1.60 | < 0.001 |
Endoluminal neointimal area (mm2) | 0.76 ± 0.29 | 0.76 ± 0.25 | 0.789 | 0.76 ± 0.29 | 0.73 ± 0.20 | 0.336 |
Abluminal neointimal area + stent/scaffold strut area (mm2) | 1.94 ± 0.57 | 1.76 ± 0.60 | 0.002 | 1.94 ± 0.57 | 1.65 ± 0.35 | < 0.001 |
Neointima | ||||||
Homogeneous | 213 (93%) | 162 (85%) | 213 (93%) | 79 (89%) | ||
Heterogeneous | 16 (7%) | 29 (15%) | 0.007 | 16 (7%) | 10 (11%) | 0.214 |
Cross-section with intraluminal mass | 3 (1.3%) | 2 (1.1%) | 1.000 | 3 (1.3%) | 2 (2.3%) | 0.622 |
Cross-section with malapposition area > 0 | 7 (3.1%) | 6 (3.1%) | 0.960 | 7 (3.1%) | 0 (0.0%) | 0.098 |
Cross-section with uncovered struts | 43 (19%) | 45 (24%) | 0.230 | 43 (19%) | 19 (21%) | 0.603 |
Cross-section with malapposed and uncovered struts | 0 | 1 (0.5%) | 0.455 | 0 | 0 (0.0%) | |
In stent/scaffold obstruction (%) | 9.59 ± 4.81 | 7.01 ± 2.52 | < 0.001 | 9.59 ± 4.81 | 8.12 ± 2.73 | 0.007 |
Stent strut level analysis | Absorb (2062) | Synergy (1880) | Absorb (2062) | Synergy (778) | ||
Uncovered struts (n, %) | 47 (2.3%) | 143 (7.6%) | < 0.001 | 47 (2.3%) | 30 (3.9%) | 0.021 |
Malapposed struts (n, %) | 7 (0.3%) | 23 (1.2%) | 0.001 | 7 (0.3%) | 1 (0.1%) | 0.692 |
Malapposed and uncovered (n, %) | 0 (0.0%) | 4 (0.2%) | 0.052 | 0 (0.0%) | 0 (0.0%) | |
Neointimal thickness per strut (mm2) | 0.06 ± 0.06 | 0.05 ± 0.04 | < 0.001 | 0.06 ± 0.06 | 0.05 ± 0.03 | < 0.001 |